While GLP‐1 receptor agonists and SGLT‐2 inhibitors both demonstrated similar increases in utilization for patients with high ASCVD risk, SGLT‐2 inhibitors were more commonly used across incident patients of other risk categories. The gene discussed is GLP1R; the disease is atherosclerosis.